Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
17.36
-0.62 (-3.45%)
At close: Oct 13, 2026, 4:00 PM EDT
17.37
+0.01 (0.06%)
After-hours: Oct 13, 2026, 7:30 PM EDT
Relay Therapeutics Revenue
Relay Therapeutics had revenue of $350.00K in the quarter ending June 30, 2026, a decrease of -48.30%. This brings the company's revenue in the last twelve months to $10.35M, up 23.86% year-over-year. In the year 2025, Relay Therapeutics had annual revenue of $15.36M with 53.44% growth. That makes Relay Therapeutics the 37,174th largest company in the world by revenue and 4,883rd in the United States.
Revenue (ttm)
$10.35M
Revenue Growth
+23.86%
P/S Ratio
367.57
Revenue / Employee
$51,238
Employees
202
Market Cap
3.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.36M | 5.35M | 53.44% |
| Dec 31, 2024 | 10.01M | -15.54M | -60.83% |
| Dec 31, 2023 | 25.55M | 24.17M | 1,749.82% |
| Dec 31, 2022 | 1.38M | -1.65M | -54.41% |
| Dec 31, 2021 | 3.03M | -79.63M | -96.34% |
| Dec 31, 2020 | 82.65M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Acadia Pharmaceuticals | 1.14B |
| Telix Pharmaceuticals | 890.79M |
| Arcutis Biotherapeutics | 463.98M |
| IDEAYA Biosciences | 234.13M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| Xenon Pharmaceuticals | 7.50M |
RLAY News
- 27 days ago - Relay Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 5 weeks ago - Relay Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 6 weeks ago - Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September - GlobeNewsWire
- 7 weeks ago - Relay Therapeutics price target raised to $29 from $28 at H.C. Wainwright - TheFly
- 1 month ago - Relay Therapeutics price target raised to $31 from $28 at JPMorgan - TheFly
- 2 months ago - Relay Therapeutics price target raised to $25 from $21 at BofA - TheFly
- 2 months ago - Relay Therapeutics price target raised to $26 from $21 at Citizens - TheFly
- 2 months ago - Relay Therapeutics price target raised to $30 from $27 at Barclays - TheFly